EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer

Rebecca C. Arend, Allison M. Davis, Przemyslaw Chimiczewski, David M. O'Malley, Diane Provencher, Ignace Vergote, Sharad Ghamande, Michael J. Birrer

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Fingerprint

Dive into the research topics of 'EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences